Ironwood Pharmaceuticals (IRWD) Operating Leases (2019 - 2026)

Ironwood Pharmaceuticals has disclosed Operating Leases across 8 years of filings, most recently posting $9.2 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $9.2 million, down 21.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.2 million (down 21.2% YoY), and the FY2025 annual result was $9.9 million, down 19.78% from the prior year.
• Operating Leases came in at $9.2 million for Q1 2026 at Ironwood Pharmaceuticals, down from $9.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $18.0 million in Q1 2022 to a low of $9.2 million in Q1 2026.
• The 5-year median for Operating Leases is $14.0 million (2024), against an average of $13.9 million.
• Across the five-year window, Operating Leases fell 9.22% in 2022 and slipped 21.2% in 2026, its largest moves.
• Ironwood Pharmaceuticals' Operating Leases stood at $16.6 million in 2022, then retreated by 12.39% to $14.5 million in 2023, then declined by 15.4% to $12.3 million in 2024, then fell by 19.78% to $9.9 million in 2025, then dropped by 6.45% to $9.2 million in 2026.
• The last three Operating Leases figures came in at $9.2 million (Q1 2026), $9.9 million (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.